As leaders in Real World Evidence Generation and experts in understanding patients and HCPs, we are here to partner with you and support with
- Broad and deep disease area understanding
- Evidence needs and gaps, incl. publications development
- Insights feeding into your strategy
The Rheumatology DSPs portfolio covers well established therapy areas alongside areas with limited treatment options and consequently, limited real-world data.
There are in-house data covering Sjogren’s disease and Systemic Sclerosis – indications where there are limited treatment options other than symptomatic management. The DSPs provide a comprehensive overview of those therapy areas, supporting market entry strategies, and there are plans to refresh these datasets in 2026 & 2027.
Dataset refresh will also cover PsA and axSpA with current in house data from 2024/25, incl. patients receiving bimekizumab. With the increasing number of established therapies, we are collecting longitudinal data on patients with PsA and axSpA receiving advanced therapies – the EXTEND programme. Whilst there are clinical trials across a range of diseases, real-world longitudinal data about patients receiving advanced therapy is scarce, making this dataset quite unique.
The fifth wave of the Lupus DSP (2024/25), covers SLE, LN and CLE, with an additional enrichment sample of patients receiving anifrolumab.
One of our longest established programmes – RA comprises of 14 waves and can be used to understand treatment market and dynamics within saturated markets and identifying patients that could still benefit from new therapies.
Finally, there are first waves of DSPs in Gout and GCA from 2024, including relevant enrichment samples in both areas.
Rheumatology Conditions Disease Specific Programmes (DSP) Portfolio
The DSPs answer a broad range of objectives, exploring in depth patient sub-groups:
- Objective and subjective disease severity: clinical outcomes & PROMs defining true disease control and what matters to patients most
- Improving patient experience across their disease journey
- Real world comparative analysis of (newly launched) treatments and impact of early vs late advanced therapy initiation
- Treatment utilisation patterns, switching and reasons for switching; steroid burden
- Patients’ quality of life, clinical and economical disease burden
- Patient equity and treatment access disparities
Topics we have published recently on include:
- Patient journey: diagnosis, management, classification - Click here to view example
- Treatment landscape and real-world drug use and effectiveness – Click here to view example
- Alignment of patient-physician perspectives – Click here to view example
- Patient unmet needs – Click here to view example
- Economic burden of illness – Click here to view example